In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IGBA Aims To Take The Fight To Originators On Trade Deals

Executive Summary

 With a permanent structure in place and a trade principles paper recently updated, the IGBA believes it is well placed to argue the case for promoting accessible medicines in international trade negotiations versus the interests of the originator industry.

You may also be interested in...



IGBA Urges Action To Ensure Sustainability

A series of global policy recommendations has been set out by the International Generic and Biosimilar Medicines Association as part of efforts to ensure a sustainable industry environment and maintain patient access to off-patent drugs.

UK Opposition Would Fight TRIPS-Plus Provisions

The UK’s main opposition party, Labour, says it would resist US pressure to raise intellectual-property protections for pharmaceuticals. And it wants to support other countries in ensuring trade negotiations do not result in stronger IP rights globally.

Congress Puts Pressure On USTR Over Deal With Canada And Mexico

More than 100 members of the US Congress have written to US Trade Representative ambassador Robert Lighthizer urging changes to the US-Mexico-Canada Agreement trade deal that is due to replace the previous NAFTA agreement, with biologic competition and access highlighted as key concerns.

Related Content

Topics

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel